Introduction {#Sec1}
============

MK801 and ketamine are derivatives of phencyclidine (PCP), which is also known as angel dust^[@CR1],[@CR2]^. These PCP-related drugs are well known to block the ionotropic N-methyl-d-aspartate receptor (NMDAr) by non-competitively binding to the internal ionic pore region of NMDAr^[@CR1]--[@CR3]^. These PCP-related NMDAr antagonists have been reported to induce various clinical symptoms, such as psychosis, schizophrenia, and hypertension. However, the mechanisms underlying these symptoms are unclear and controversial^[@CR4]--[@CR7]^. The direct effects of ketamine and PCP on dopamine D~2~ and serotonin 5-hydroxytryptamine (HT)~2~ receptors have been suggested to be implicated in the pathogenesis of schizophrenia^[@CR8]--[@CR11]^. In agreement with this, a previous study showed that 5-HT~2A~ receptor (5-HT~2A~R)-mediated arterial contraction was facilitated by ketamine^[@CR12]^, which was suggested to be the mechanism underlying ketamine-induced hypertension. In addition, NMDAr antagonists, including MK801 and ketamine, enhanced the head-twitch response, a 5-HT2R-mediated behavior, in reserpine-treated mice^[@CR13]^.

Voltage-gated K^+^ channel (Kv) currents in arterial smooth muscle cells have been reported to be blocked by ketamine and MK801^[@CR14],[@CR15]^. However, reports on the effects of MK801 or ketamine on the specific subtype(s) of Kv are not available yet. Because Kv channels such as Kv1.5 in the arterial smooth muscle play a critical role in 5-HT~2A~R signaling^[@CR16]--[@CR18]^, whether Kv1.5 is blocked by MK801 and ketamine is worth examining. Moreover, Kv1.5 plays critical roles in regulating the membrane excitabilities of atrial cardiomyocytes^[@CR19],[@CR20]^ and several neuronal and glial cells, such as pituitary neurons and Schwann cells^[@CR21],[@CR22]^. In this study, we report that MK801 and ketamine facilitated the response of 5-HT~2A~R activation in a membrane potential (E~m~)-dependent manner and directly blocked Kv1.5 channels from the extracellular side. From these findings, we suggest that 5-HT~2A~R-Kv1.5 may play an important role as a receptor-effector module in response to 5-HT. Moreover, 5-HT~2A~R-Kv1.5 is a promising target of MK801 and ketamine in the pathogenesis of clinical symptoms induced by these PCP derivative NMDAr antagonists.

Materials and methods {#Sec2}
=====================

Animals and tissue preparation {#Sec3}
------------------------------

All experiments were conducted in accordance with the National Institutes of Health guidelines for the care and use of animals. The Institutional Animal Care and Use Committee of Konkuk University approved this study. Mesenteric arterial rings and aorta rings were prepared, as previously described^[@CR17],[@CR23]^. The carotid arteries of male Sprague**-**Dawley (SD) rats (10--11 weeks old) were cut to exsanguinate the rats under deep ketamine-xylazine anesthesia or after exposure to 100% carbon dioxide. The branches of the superior mesenteric arteries and thoracic aorta were promptly isolated and placed in physiological saline solution (PSS) containing 136.9 mM NaCl, 5.4 mM KCl, 1.5 mM CaCl~2~, 1.0 mM MgCl~2~, 23.8 mM NaHCO~3~, 1.2 mM NaH~2~PO~4~, 0.01 mM ethylenediaminetetraacetic acid (EDTA), and 5.5 mM glucose. The arteries were carefully cleaned of fat and connective tissues under a stereomicroscope and prepared as rings (3.5 mm in length) for tension measurements. The endothelium was mechanically removed with a fine stainless-steel wire. The endothelial removal was confirmed by the absence of relaxation induced by acetylcholine (10 μM) after norepinephrine (NE; 1--10 μM) or 5-HT (1--10 μM)-induced contraction.

Tension measurements {#Sec4}
--------------------

The isometric tension of the arterial rings was measured, as previously described^[@CR17],[@CR23]^. The arterial rings were mounted vertically on two L-shaped stainless-steel wires in a 3-mL tissue chamber. One wire was attached to a micromanipulator and the other to an isometric force transducer (FT03; Grass, West Warwick, RI, USA). The changes in isometric force were digitally acquired at 1 Hz with a PowerLab data acquisition system (ADInstruments, Colorado Springs, CO, USA). Resting tension was set to 1 g (mesenteric arterial rings) or 2 g (aorta) by the micromanipulator. After equilibration for 60 min under resting tension in a tissue chamber filled with PSS, the rings were sequentially exposed to 70 mM KCl PSS (10 min) and PSS (15 min) thrice for stabilization. High KCl (70 mM) PSS was prepared by replacing NaCl with equimolar KCl in PSS. The bathing solutions were thermostatically controlled at 37 °C and continuously saturated with a mixture of 95% O~2~ and 5% CO~2~ to achieve a pH of 7.4.

Cell culture and transfection {#Sec5}
-----------------------------

Chinese hamster ovary (CHO) cells expressing Kv1.5 derived from the rat brain were used for electrophysiological recordings^[@CR24],[@CR25]^. Kv1.5 cDNA^[@CR26]^ was transferred into the plasmid expression vector pCR3.1 (Invitrogen Corporation, San Diego, CA, USA). CHO cells were transfected with Kv1.5 cDNA using FuGENE™6 reagent (Boehringer Mannheim, Indianapolis, IN, USA). The transfected cells were cultured in Iscove's modified Dulbecco's medium (Invitrogen Corporation) supplemented with 10% fetal bovine serum, 2 mM glutamine, 0.1 mM hypoxanthine, 0.01 mM thymidine, and 300 µg/mL G418 (A.G. Scientific, San Diego, CA, USA) in a 95% humidified air-5% CO~2~ incubator at 37 °C. The cultures were passaged every 4--5 days with a brief trypsin-EDTA treatment and then seeded onto glass coverslips (diameter: 12 mm, Fisher Scientific, Pittsburgh, PA, USA) in a Petri dish. After 12--24 h, the cell-attached coverslips were used for electrophysiological recordings.

Electrophysiology {#Sec6}
-----------------

Kv1.5 currents were recorded from CHO cells using the whole-cell patch-clamp technique^[@CR27]^ at room temperature (22--23 °C). Micropipettes fabricated from glass capillary tubing (PG10165-4; World Precision Instruments, Sarasota, FL, USA) with a double-stage vertical puller (PC-10; Narishige, Tokyo) had a tip resistance of 2--3 MΩ when filled with the pipette solution. Whole-cell currents were amplified with an Axopatch 200 B amplifier (Molecular Devices, Sunnyvale, CA, USA), digitized with the Digidata 1440 A (Molecular Devices) at 5 kHz, and low-pass filtered with a four-pole Bessel filter at 2 kHz. Capacitive currents were canceled, and series resistance was compensated at 80% with the amplifier, while leak subtraction was not used. The generation of voltage commands and acquisition of data were controlled with pClamp 10.1 software (Molecular Devices) running on an IBM-compatible Pentium computer. The recording chamber (RC-11, Warner Instrument Corporation, Hamden, CT, USA) was continuously perfused with the bath solution (see below for composition) at a rate of 1 mL/min.

The intracellular pipette solution for whole-cell recordings contained 140 mM KCl, 5 mM NaCl, 5 mM MgATP, 10 mM 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid (HEPES), and 10 mM 1,2-bis(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) and was adjusted to a pH of 7.2 with KOH. The bath solution for whole-cell recordings contained 143 mM NaCl, 5.4 mM KCl, 0.33 mM NaH~2~PO~4~, 1.8 mM CaCl2, 0.5 mM MgCl~2~, 5 mM HEPES, and 11 mM glucose and was adjusted to a pH of 7.35--7.40 with NaOH.

Drugs {#Sec7}
-----

All chemicals, including ketamine and MK801, were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Data analysis {#Sec8}
-------------

Origin 8.0 software (Microcal Software, Inc., Northampton, MA, USA) was used for data analysis. The results are shown as the means ± SEM. Paired or independent Student's *t*-tests were performed to test for significance as appropriate, and *p* \< 0.05 was regarded as significant. For analysis of the concentration--response curves (CRCs), Student's *t*-tests were performed at a given concentration to compare the two groups. When the two groups were not statistically different at any given concentration, the differences in the CRCs were determined to be N.S. (not significant) (Fig. [1c--e, g](#Fig1){ref-type="fig"}, and Fig. [2c](#Fig2){ref-type="fig"}).Fig. 1Facilitation of 5-HT~2A~R-mediated arterial contractions by MK801 and ketamine.**a** Concentration-response curves (CRCs) of 5-HT-induced rat mesenteric arterial contractions in the absence and presence of MK801. **b** CRC of MK801-induced rat mesenteric arterial contractions in the presence of a physiological concentration (200 nM) of 5-HT. **c** CRC of (+) and (−) MK801-induced rat mesenteric arterial contractions in the presence of 200 nM of α-methyl 5-HT, a selective 5-HT~2A~R agonist. **d** Membrane potential (E~m~)-independent CRCs of 5-HT-induced rat mesenteric arterial contractions in the absence and presence of MK801 after pretreatment with 70 mM KCl and nifedipine (1 µM). **e** E~m~-independent CRCs of 5-HT-induced rat mesenteric arterial contractions in the absence and presence of ketamine after pretreatment with 70 mM KCl and nifedipine (1 µM). **f** CRC of MK801-induced rat mesenteric arterial contractions in the absence and presence of high (70 mM) KCl. **g** CRCs of phenylephrine-induced rat aorta contractions in the absence and presence of MK801. N in parentheses indicates the number of animals examined. \**p* \< 0.05; \*\**p* \< 0.01; N.S. not significantFig. 2Inhibition of Kv1.5 currents by MK801 enantiomers recorded from CHO cells overexpressing Kv1.5.**a** Representative Kv1.5 current tracings elicited by voltage steps shown in the figure inset in the absence and presence of MK801 (100 and 300 µM). **b** Kv 1.5 current amplitudes at + 50 mV are plotted against time. The period of application of various concentrations of MK801 is indicated as solid bars. **c** CRCs of (+) and (−) MK801 enantiomer-induced Kv1.5 inhibition. N in parentheses indicates the number of cells examined. N.S. not significant

Results {#Sec9}
=======

Em-dependent facilitation of the 5-HT2AR-mediated arterial contraction induced by MK801 and ketamine {#Sec10}
----------------------------------------------------------------------------------------------------

5-HT~2A~Rs have been previously reported to mediate the effect of 5-HT in rat mesenteric arteries^[@CR17]^, and ketamine has been shown to facilitate 5-HT~2A~R-mediated contraction without unmasking other subtypes of 5-HT receptors, such as 5-HT1B or 5-HT2B receptors^[@CR12]^. In this study, we examined whether MK801, another PCP derivative, also has similar effects on 5-HT~2A~R-mediated arterial contraction. The CRC of 5-HT-induced contraction of rat mesenteric arteries was evidently shifted to the left in the presence of MK801 (10 µM, Fig. [1a](#Fig1){ref-type="fig"}), indicating that MK801 also facilitated the 5-HT~2A~R-mediated response in rat mesenteric arteries. Furthermore, in the presence of a physiologically relevant concentration of 5-HT (200 nM, which is close to the resting plasma level of 5-HT), MK801 contracted the mesenteric arterial rings (Fig. [1b](#Fig1){ref-type="fig"}) in a concentration-dependent manner. However, MK801 alone, similar to ketamine^[@CR12]^, had a negligible effect on arterial contraction in the control condition without 5-HT (Fig. [1f](#Fig1){ref-type="fig"}). The CRCs of MK801-induced arterial contractions in the presence of 200 nM α-methyl 5-HT, which is a selective agonist of 5-HT2Rs, were similar between the (+) and (−) MK801 enantiomers (Fig. [1c](#Fig1){ref-type="fig"}), although the potencies of these optical isomers in blocking NMDArs are known to be quite different^[@CR1],[@CR2]^.

To further examine whether this facilitating effect of MK801 on 5-HT~2A~R-mediated arterial contraction is related to ion channel regulation, we examined the effect of MK801 on E~m~-independent arterial contraction. The E~m~-independent arterial contraction was isolated by pretreatment of the arterial rings with both nifedipine (1 µM) and high KCl (70 mM)^[@CR17]^. Notably, the left shift of the CRC of the 5-HT~2A~R-mediated arterial contraction by MK801 was not observed when the E~m~-dependent 5-HT response was excluded (Fig. [1d](#Fig1){ref-type="fig"}). Similarly, the facilitating effect of ketamine^[@CR12]^ was not observed when the E~m~-dependent 5-HT response was excluded (Fig. [1e](#Fig1){ref-type="fig"}). These results suggest that the PCP derivatives MK801 and ketamine facilitate the 5-HT~2A~R-mediated response by regulating ion channels and E~m~. In support of this E~m~-dependent facilitation hypothesis, MK801 did not contract the high (70 mM) KCl-precontracted arterial rings (Fig. [1f](#Fig1){ref-type="fig"}).

To define whether the facilitating effects of MK801 on arterial contraction were receptor-specific, we further examined the effect of MK801 on the CRCs of phenylephrine-induced vasocontraction. In contrast to the contractions induced by 5-HT, MK801 had negligible effects on the CRCs of phenylephrine-induced vasocontraction (Fig. [1g](#Fig1){ref-type="fig"}).

Direct inhibition of Kv1.5 by MK801 and ketamine from the extracellular side {#Sec11}
----------------------------------------------------------------------------

The response of 5-HT~2A~Rs is mediated by a decrease in Kv conductance^[@CR9],[@CR16]--[@CR18]^. Noticeably, hallucinogens other than PCP derivatives (such as LSD) have also been reported to modulate Kv channel activity, acting at 5-HT2Rs^[@CR9]^. In particular, Kv1.5 has been reported to be primarily responsible for mediating 5-HT~2A~R activation in the arteries^[@CR18]^. If MK801 and ketamine inhibit Kv1.5, these drugs could be hypothesized to augment 5-HT~2A~R signaling by facilitating 5-HT~2A~R-mediated Kv1.5 inhibition and E~m~ depolarization. To address this hypothesis, we examined the effect of MK801 on Kv1.5 currents in CHO cells stably overexpressing Kv1.5. MK801 concentration-dependently \[IC~50~ = 156.8 ± 7.9 μM, Hill coefficient = 1.03 ± 0.05 for (−) MK801; IC~50~ = 157.3 ± 14.0 μM, Hill coefficient = 0.93 ± 0.03 for (+) MK801\] inhibited Kv1.5 currents (Fig. [2a--c](#Fig2){ref-type="fig"}). The inhibition of Kv1.5 currents upon MK801 application was rapid and reversible (Fig. [2b](#Fig2){ref-type="fig"}). The optical isomers of MK801 \[(+) and (−) MK801\] inhibited Kv1.5 currents with similar potency and efficacy (Fig. [2a, c](#Fig2){ref-type="fig"}).

To determine whether MK801 blocks Kv1.5 from the extracellular or intracellular side, we examined the effect of MK801 using a pipette containing MK801. When the Kv1.5 currents were recorded with a pipette containing MK801 (up to 1 mM), the amplitudes of Kv1.5 currents were still comparable to those recorded under the control condition without MK801 in the pipette (Fig. [3](#Fig3){ref-type="fig"}). Moreover, Kv1.5 current inhibition by the bath application of MK801 was not affected by MK801 in the pipette (Fig. [2a, c](#Fig2){ref-type="fig"}). These results indicate that MK801 inhibited Kv1.5 from the extracellular side.Fig. 3Inhibition of Kv1.5 currents by extracellular MK801 recorded with MK801-containing pipettes.**a** Representative Kv1.5 current tracings elicited by voltage steps shown in the figure inset with the pipette containing 300 µM MK801 in the absence and presence of various concentrations of MK801 in the bath. **b** Representative Kv1.5 current tracings with the pipette containing 1 mM MK801 in the absence and presence of various concentrations of MK801 in the bath. Similar results from 3 further independent experiments

Similarly, ketamine \[(+) and (−) racemate\] inhibited Kv1.5 from the extracellular side (Fig. [4a](#Fig4){ref-type="fig"}). The ketamine-induced Kv1.5 inhibition was also rapid and reversible after wash-out (Fig. [4b](#Fig4){ref-type="fig"}). The potency of ketamine in inducing Kv1.5 inhibition was relatively lower than that of MK801 (IC~50~ = 640.5 ± 33.2 μM, Hill coefficient = 1.12 ± 0.06, Fig. [4a--c](#Fig4){ref-type="fig"}).Fig. 4Inhibition of Kv1.5 by ketamine.**a** (upper) Representative Kv1.5 current tracings elicited by voltage steps shown in the figure inset in the absence and presence of ketamine (100, 300, and 1000 µM); lower, Representative Kv1.5 current tracings recorded with the pipette containing ketamine (1000 µM) in the absence and presence of bath ketamine (100, 300, and 1000 µM). **b** Kv1.5 current amplitudes at +50 mV are plotted against time. The period of application of various concentrations of ketamine is indicated as solid bars. **c** CRCs of ketamine-induced Kv1.5 inhibition. N in parentheses indicates the number of cells examined

Discussion {#Sec12}
==========

In our previous study, we reported that ketamine facilitated 5-HT~2A~R-mediated arterial contraction^[@CR12]^. The findings of this study further demonstrated that MK801, another PCP derivative NMDAr antagonist, also similarly facilitated 5-HT~2A~R-mediated arterial contraction. The facilitation of 5-HT~2A~R-mediated arterial contraction by MK801/ketamine was E~m~-dependent, indicating that ion channel regulation is critically involved. Accordingly, Kv1.5 inhibition was suggested to play a role in mediating the facilitating effect of MK801/ketamine. To the best of our knowledge, this is the first report to show E~m~-dependent facilitation of 5-HT~2A~R-mediated arterial contraction, as well as Kv1.5 inhibition by MK801 and ketamine. We believe that the findings of this study suggest that 5-HT~2A~R-Kv1.5 may function as an important receptor-effector module and an important target of MK801 and ketamine.

Signaling of 5-HT2ARs and their regulation by MK801 and ketamine {#Sec13}
----------------------------------------------------------------

Neither the facilitation of the 5-HT~2A~R response nor the inhibition of Kv1.5 by MK801/ketamine shown in this study were related to NMDAr regulation based on the following observations: (1) MK801/ketamine inhibited Kv1.5, which was overexpressed in CHO cells. (2) The inhibition of Kv1.5 by MK801 was not stereospecific, although inhibition of NMDArs by MK801 is known to be stereospecific. (3) The facilitation of 5-HT~2A~R-mediated arterial contraction by MK801 was not stereospecific either. These observations indicate that MK801/ketamine interacted with the 5-HT~2A~R-Kv1.5 receptor-effector module. In addition, MK801-induced facilitation was receptor-specific; 5-HT~2A~Rs but not α-adrenoceptors were facilitated by MK801 (Fig. [1g](#Fig1){ref-type="fig"}).

In the rat aorta and mesenteric arteries, 5-HT~2A~R activation has been reported to be followed by Src phosphorylation and consequent Kv inhibition^[@CR17],[@CR28]^. Because Kv inhibition is a downstream effector step in 5-HT~2A~R-mediated signaling, \~70% of 5-HT~2A~R-mediated arterial contraction was dependent on E~m~ depolarization^[@CR17]^. In this regard, as a mechanism for MK801/ketamine-induced facilitation of 5-HT~2A~Rs, the direct interaction of MK801 and ketamine with 5-HT~2A~Rs^[@CR8]^ and consequent facilitation of Src phosphorylation^[@CR17]^ could be reasoned to contribute to the MK801 and ketamine-induced facilitation of the 5-HT~2A~R-mediated response. In agreement with this hypothesis, a previous study reported that PCP derivatives have some direct partial agonist or allosteric activator effects on 5-HT2 and D2 receptors^[@CR8],[@CR11]^. Alternatively, as shown in this study, the direct inhibition of Kv1.5 by MK801/ketamine could potentiate the Kv1.5 inhibition mediated by 5-HT~2A~R activation. Notably, the facilitating concentrations of MK801 (maximal at \~10 µM) and ketamine (maximal at \~30 µM) on 5-HT~2A~Rs are relatively lower than the inhibiting concentrations of MK801 and ketamine on Kv1.5 (IC~50~ = \~150 and \~600 nM, respectively). The native 4-aminopyridine-sensitive Kv currents in the mesenteric arterial smooth muscle cells were also inhibited by MK801 and ketamine with similar potencies as the Kv1.5 current^[@CR14],[@CR15]^. We interpreted these observations to indicate that low concentrations (around threshold for Kv1.5 inhibition) of MK801 and ketamine make Kv1.5 ready to be blocked by low concentrations of 5-HT, i.e., cooperative actions of threshold levels of 5-HT on 5-HT~2A~Rs and MK801/ketamine on Kv1.5 facilitate 5-HT action. This interpretation likely explains the finding that MK801/ketamine only shifted the CRCs of 5-HT-induced arterial contraction without increasing the maximal efficacy (Fig. [1a](#Fig1){ref-type="fig"}). Furthermore, the facilitating actions of MK801 and ketamine notably occurred at their clinical concentrations with physiological concentrations of 5-HT, reinforcing their clinical relevance. At concentrations of MK801 above 30 µM, the facilitating effect on 5-HT~2A~R-mediated arterial contraction was decreased (Fig. [1b, c](#Fig1){ref-type="fig"}), although the inhibitory effect on Kv1.5 became stronger (Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). A similar observation was found with ketamine^[@CR12]^, which is probably due to some other non-specific effect, such as inhibition of L-type voltage-gated Ca^2+^ channels or Ca^2+^-induced Ca^2+^ release from the sarcoplasmic reticulum^[@CR29]--[@CR31]^. In agreement, MK801 also inhibited the 70-mM KCl-induced arterial contraction at concentrations above 30 µM (Fig. [1f](#Fig1){ref-type="fig"}).

Both MK801 and ketamine directly inhibit Kv1.5 from the extracellular side {#Sec14}
--------------------------------------------------------------------------

Although previous studies reported that MK801 and ketamine inhibited the native 4-aminopyridine-sensitive Kv current in dispersed rat mesenteric arterial smooth muscle cells^[@CR14],[@CR15]^, this is the first study showing the inhibition of Kv1.5 by MK801 and ketamine. The potency of MK801 in inhibiting Kv1.5 was higher than that of ketamine. Accordingly, MK801 facilitated the 5-HT~2A~R response at concentrations (from 0.3 µM and peak at 10 µM; Fig. [1b](#Fig1){ref-type="fig"}) lower than those of ketamine (from 10 µM and peak at 30 µM; Fig. 1a of ref. ^[@CR12]^). Upon application, Kv1.5 inhibition by MK801 and ketamine was very rapid and occurred from the extracellular side (Figs. [2](#Fig2){ref-type="fig"}--[4](#Fig4){ref-type="fig"}), indicating that the direct inhibition of Kv1.5 by MK801 and ketamine is important in regulating the electrical excitabilities of atrial myocytes and glial and neuronal cells^[@CR19]--[@CR22]^. In pulmonary arterial smooth muscle cells, Kv1.5 was convincingly demonstrated to be an effector of 5-HT~2A~R signaling^[@CR18]^. Therefore, whether the inhibition of Kv1.5 and related facilitation of the 5-HT~2A~R-induced response is involved in the pathogenesis of clinical symptoms in MK801/ketamine-induced experimental animal models of schizophrenia, hypertension, and dissociative anesthesia should be considered^[@CR4],[@CR5],[@CR7],[@CR8],[@CR32]--[@CR34]^. Notably, serotonergic mechanisms are critically involved in the pathogenesis of psychosis and schizophrenia^[@CR6],[@CR35],[@CR36]^. The precise mechanism underlying the MK801 and ketamine-induced facilitation of 5-HT~2A~Rs and Kv1.5 inhibition and their clinical outcomes warrants future study. In addition, the effects of other Kv subtypes, such as Kv1.1, Kv1.2, and Kv1.6, and their role in the facilitation of 5-HT2Rs need to be evaluated^[@CR9]^.

In conclusion, MK801 and ketamine facilitate the 5-HT~2A~R activation response in an E~m~-dependent manner, especially at lower, physiologically relevant concentrations of 5-HT, likely by acting on the 5-HT~2A~R-Kv1.5 receptor-effector module, which is independent of NMDArs.
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